---
title: "Iterum Therapeutics plc (ITRMF.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ITRMF.US.md"
symbol: "ITRMF.US"
name: "Iterum Therapeutics plc"
industry: "Pharmaceuticals"
datetime: "2026-04-06T01:36:43.823Z"
locales:
  - [en](https://longbridge.com/en/quote/ITRMF.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ITRMF.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ITRMF.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ITRMF.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ITRMF.US.md)


# Iterum Therapeutics plc (ITRMF.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.iterumtx.com](https://www.iterumtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-05T04:30:17.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 164 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 11.76% |  |
| P/B Ratio | -0.30 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2219078.53 |  |
| Revenue | 390000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 285.48% | A |
| Profit Margin | -6913.08% | E |
| Gross Margin | 94.87% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 11.76% | C |
| Total Assets YoY | 104.11% | A |
| Net Assets YoY | 35.86% | A |
| Cash Flow Margin | -1.45% | D |
| OCF YoY | 0.00% | C |
| Turnover | 0.02 | E |
| Gearing Ratio | 122.71% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Iterum Therapeutics plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "11.76%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.30",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2219078.53",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "390000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "285.48%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-6913.08%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "94.87%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "11.76%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "104.11%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "35.86%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-1.45%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "122.71%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.08 | 66/189 | - | - | - |
| PB | -0.30 | 204/189 | - | - | - |
| PS (TTM) | 5.69 | 105/189 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | C | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | C | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | C | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ITRMF.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ITRMF.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ITRMF.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ITRMF.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**